Flu Medications — Prescription Antivirals

Prescription antiviral medications can shorten the duration of influenza and reduce the risk of serious complications — but only when used correctly and started early. This guide covers the four FDA-approved antiviral drugs for influenza, how they work, who qualifies for treatment, and what to expect.

How Antiviral Flu Medications Work

Unlike antibiotics, which target bacteria, antiviral drugs work directly against the influenza virus. They do not "kill" the virus outright. Instead, they block the virus's ability to replicate inside your cells. By slowing viral reproduction, antivirals give your immune system the upper hand — the viral load peaks lower and clears faster, which translates to a shorter illness and lower risk of complications.

The two main mechanisms are:

• Neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) — Block the neuraminidase enzyme that the flu virus uses to escape infected cells and spread to new ones. Without this enzyme, newly formed virus particles remain stuck to the cell surface and cannot infect other cells.
• Cap-dependent endonuclease inhibitor (baloxavir marboxil) — Blocks a different viral enzyme that the virus needs to hijack the host cell's machinery for its own replication. It acts at an earlier stage in the viral life cycle than neuraminidase inhibitors.

The Four FDA-Approved Antivirals

Oseltamivir (Tamiflu®)

Route: Oral (capsule or liquid suspension)
Approved for: Treatment of uncomplicated influenza in patients aged 2 weeks and older; prophylaxis in patients aged 1 year and older.
Standard dose: 75 mg twice daily for 5 days (treatment); 75 mg once daily for 10 days (prophylaxis).
Key evidence: A 2014 Cochrane review of over 20 trials found that oseltamivir reduced the duration of flu symptoms by approximately 16.8 hours in adults (from about 7 days to about 6.3 days). In children, the reduction was about 29 hours. More importantly, oseltamivir reduced the risk of lower respiratory tract complications requiring antibiotics by 44% in adults.

Zanamivir (Relenza®)

Route: Inhaled powder via Diskhaler device
Approved for: Treatment of uncomplicated influenza in patients aged 7 years and older; prophylaxis in patients aged 5 years and older.
Standard dose: Two 5 mg inhalations (10 mg total) twice daily for 5 days.
Key considerations: Zanamivir is not recommended for people with underlying respiratory disease (asthma, COPD) due to the risk of bronchospasm. It may be an option when resistance to oseltamivir is suspected.

Peramivir (Rapivab®)

Route: Intravenous (IV) — single dose
Approved for: Treatment of uncomplicated influenza in patients aged 6 months and older.
Standard dose: Single IV infusion over 15–30 minutes (600 mg for adults).
Key considerations: The main advantage is the single-dose format, useful for patients who cannot take oral medications or absorb them reliably. A 2016 trial showed peramivir reduced time to symptom resolution by about 21 hours compared to placebo.

Baloxavir Marboxil (Xofluza®)

Route: Oral — single dose
Approved for: Treatment of uncomplicated influenza in patients aged 5 years and older; post-exposure prophylaxis in patients aged 5 years and older.
Standard dose: Single oral dose based on body weight (40 mg for patients under 80 kg; 80 mg for patients 80 kg and over).
Key evidence: In the CAPSTONE-1 trial, baloxavir reduced the median time to symptom relief by about 26 hours versus placebo. It also reduced viral load more rapidly than oseltamivir — viral levels dropped below detection within 24 hours in many patients, compared to 72 hours with oseltamivir. The single-dose convenience is a significant advantage.

The 48-Hour Window: Why Timing Matters

All four antivirals are most effective when started within 48 hours of symptom onset. The mechanism is straightforward: the drugs work by limiting viral replication, and viral replication peaks within the first 24–72 hours of illness. Starting treatment after the virus has already peaked provides diminishing returns.

However, the CDC recommends that antiviral treatment should still be considered after 48 hours in certain high-risk groups, including:

• Hospitalized patients with confirmed or suspected influenza
• Patients with severe, complicated, or progressive illness
• People at high risk for complications (see below)

For these groups, treatment may still provide benefit even when started beyond the 48-hour window.

Who Should Get Antiviral Treatment?

The CDC recommends that antiviral treatment be started as soon as possible for anyone with confirmed or suspected influenza who falls into one of these categories:

• Hospitalized patients — regardless of how long symptoms have been present
• Severe or progressive illness — regardless of prior health status
• High-risk outpatients, including:
  • Children under 2 years (especially under 6 months)
  • Adults 65 years and older
  • Pregnant women and those up to 2 weeks postpartum
  • People with chronic medical conditions: asthma, COPD, heart disease, diabetes, kidney disease, liver disease, immunocompromised states, neurological conditions
  • People with BMI of 40 or higher
  • Residents of nursing homes and long-term care facilities

For otherwise healthy adults with uncomplicated flu-like illness, the decision to prescribe antivirals should be individualized. The benefit (about one day less of symptoms) must be weighed against cost, side effects, and the need to start treatment promptly.

Side Effects of Antiviral Medications

Oseltamivir (Tamiflu)

• Most common: Nausea and vomiting (5–10% of patients). Taking with food can reduce gastrointestinal side effects.
• Less common: Headache, dizziness, insomnia.
• Rare: Neuropsychiatric events (confusion, abnormal behavior) have been reported, primarily in children and adolescents in Japan. A causal relationship has not been established, and these events have also been reported in influenza patients not taking antivirals.

Zanamivir (Relenza)

• Most common: Nasal discomfort, throat irritation, cough.
• Serious concern: Bronchospasm and decline in lung function in patients with asthma or COPD. Contraindicated in people with underlying airways disease.

Peramivir (Rapivab)

• Most common: Diarrhea, nausea, vomiting.
• Less common: Neutropenia (low white blood cell count), generally mild and transient.

Baloxavir (Xofluza)

• Most common: Diarrhea (3%), bronchitis (3%). Generally well-tolerated with a side effect profile similar to placebo.
• Important interaction: Dairy products, calcium-fortified beverages, antacids, and supplements containing calcium, magnesium, iron, zinc, or selenium can significantly reduce absorption. Avoid these for several hours before and after dosing.

Antiviral Resistance

Antiviral resistance is monitored globally by the WHO's Global Influenza Surveillance and Response System (GISRS). Current surveillance data (2025–2026 season) shows:

• Oseltamivir resistance remains low (<1%) in circulating influenza A(H1N1)pdm09 and A(H3N2) viruses, though higher rates have been seen in some seasons.
• Baloxavir resistance-associated mutations have been detected at rates of 2–10% in treated patients, though person-to-person transmission of resistant strains appears limited.
• Almost all circulating influenza viruses remain susceptible to all four antivirals as a class, but resistance patterns can change between seasons.

Post-Exposure Prophylaxis

All four antivirals can be used for prevention after exposure to influenza. The CDC recommends considering chemoprophylaxis for:

• People at high risk for complications who have had close contact with a confirmed flu case
• Residents of institutional settings during outbreaks
• Unvaccinated high-risk individuals during community outbreaks

However, chemoprophylaxis is not a substitute for vaccination. The flu vaccine remains the primary prevention strategy.

Key Takeaways

• Antiviral medications can shorten flu duration by 1–2 days and reduce complications, but must be started within 48 hours of symptom onset for maximum benefit.
• Oseltamivir (Tamiflu) is the most commonly prescribed and has the most extensive evidence base.
• Baloxavir (Xofluza) offers the convenience of a single dose and faster viral clearance but carries a higher risk of resistance emergence.
• Antivirals are strongly recommended for high-risk patients regardless of illness duration.
• Side effects are generally mild and manageable; gastrointestinal symptoms are the most common.
• Prompt treatment is essential — if you suspect influenza and are in a high-risk group, contact your healthcare provider immediately.